Gilead submits lymphoma candidate idelalisib for FDA approval

09/12/2013 | American City Business Journals

Gilead Sciences filed an application with the FDA for approval to market its oral drug idelalisib for treatment of patients with indolent non-Hodgkin lymphoma who don't respond to Rituxan and chemotherapy with an alkylating agent. A similar application is being prepared for Europe.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX